

References

S-238

1. Ramlawi B, Gammie J. Mitral valve surgery: Current minimally invasive and transcatheter options. *Methodist DeBakey Cardiovasc J.* 2016;12(1):20–26.
2. Nishimura R, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guidelines for the management of patients with valvular heart disease. *J Am Coll Cardiol.* 2017; 70(2):252-289.
3. Lazam S, Vanoverschelde J, Tribouilloy C, et al. Twenty-year outcome after mitral repair versus replacement for severe degenerative mitral regurgitation. Analysis of a large, prospective, multicenter international registry. *Circulation.* 2016;116.
4. Sorajja P, Mack M, Vemulapalli S, et al. Initial experience with commercial transcatheter mitral valve repair in the United States. *J Am Coll Cardiol.* 2016;67(10):1129-1140.
5. Alozie A, Paranskaya L, Westphal B, et al. Clinical outcomes of conventional surgery versus MitraClip® therapy for moderate to severe symptomatic mitral valve regurgitation in the elderly population: An institutional experience. *BMC Cardiovasc Disord.* 2017;17:85.
6. Hayes, Inc., Hayes Health Technology Assessment. Minimally invasive thoracotomy for mitral valve replacement. Lansdale, PA: Hayes, Inc.; Published Nov 2014, Annual Review 11/2018. Accessed 7/9/2019.
7. Hayes, Inc., Hayes Evidence Analysis Research Brief. MitraClip for the treatment of children with congenital mitral valve cleft. Lansdale, PA: Hayes, Inc. Published April 2019.
8. Mkalaluh S, Szczeckowicz M, Karck M, Weyman A. Failed MitraClip therapy: surgical revision in high-risk patients. *J Cardiothorac Surg.* 2019;14:75
9. Nishimura RA, O’Gara PT, Bavaria JE, Brindis RG, et al. 2019 AATS/ACC/ASE/SCAI/STS expert consensus systems of care document: a proposal to optimize care for patients with valvular heart disease: A joint report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol* 2019;73(20):2609-2635.
10. Stone GW, Lindenfeld JA, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med.* 2018;379:2307-18.
11. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J.* 2017;38(36):2739-2791.
12. Hayashida K, Yasuda S, Matsumoto T, et al. AVJ-514 Trial- baseline characteristics and 30-day outcomes following MitraClip ® Treatment in a Japanese cohort. *Circ J.* 2017;81(8):1116-1122.

13. Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes With transcatheter mitral valve repair in the United States: An STS/ACC TVT Registry Report. *J Am Coll Cardiol.* 2017;70(19):2315-2327.
14. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. *N. Engl. J. Med.* 2018;379(24).
15. Atianzar, KK, Zhang, MM, Newhart, ZZ, Gafoor, SS. Why did COAPT win while MITRA-FR failed? Defining the appropriate patient population for MitraClip. *Interv Cardiol,* 2019;14(1).
16. Nishimura RA, Bonow RO. Percutaneous Repair of Secondary Mitral Regurgitation – A tale of two trials. *N Engl J Med.* 2018;379(24): 2374-2376.
17. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused update of the 2013 ACCF/AHA Guideline for the management of heart failure. *J Card Fail.* 2017;23(8):628-651.
18. Takagi H, Ando T, Umemoto T, et al. A review of comparative studies of Mitraclip versus surgical repair for mitral regurgitation. *Int J Cardiol.* 2017;228:289-294.
19. Takagi H, Hari Y, Kawai N, Ando T, ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of valve-in-valve and valve-in-ring transcatheter mitral valve implantation. *J Interv Cardiol.* 2018;31(6):899-906.
20. Hu J, Chen Y, Cheng S, et al. Transcatheter mitral valve implantation for degenerated mitral bioprostheses or failed surgical annuloplasty rings: A systematic review and meta-analysis. *J Card Surg.* 2018;33(9):508-519.
21. Novitas Solutions, Inc., LCD L35448. Revised 09/26/2019 (R16).
22. Novitas Solutions, Inc., LCA A53252. Revised 07/01/2020 (R25), 09/24/2020 (R26).
23. InterQual® Level of Care Criteria 2019. Acute Care Adult. Change Healthcare, LLC.
24. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. *J Am Coll Cardiol.* 2017;70(2):252-289.
25. Kumar A, Al-Khafaji J, Shariff M, et al. Percutaneous mitral valve repair for secondary mitral valve regurgitation: A systematic review and meta-analysis. *Eur J Intern Med.* 2020.
26. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. *N Engl J Med.* Dec 13 2018;379(24):2297-2306.

27. Lung B, Armoiry X, Vahanian A, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. *Eur J Heart Fail.* 2019;21(12):1619-1627.
28. Nishimura RA, Bonow RO. Percutaneous Repair of Secondary Mitral Regurgitation - A Tale of Two Trials. *N Engl J Med.* 2018; 379(24):2374-2376.
29. Buzzatti N, Van Hemelrijck M, Denti P, et al. Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: A propensity-weighted analysis. *J Thorac Cardiovasc Surg.* 2019;158(1):86-94.e1.
30. Kapadia SR, Huded CP, Kodali SK, et al. Stroke after surgical versus transfemoral transcatheter aortic valve replacement in the partner trial. *J. Am. Coll. Cardiol.* 2018;72(20).
31. Baron SJ, Arnold SV, Reynolds MR, et al. Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US extreme risk trial. *Am Heart J.* 2017;194:39-48.
32. Panoulas VF, Francis DP, Ruparelia N, et al. Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients. *Int J Cardiol.* 2018;250:66-72.
33. Deeb GM, Reardon MJ, Chetcuti S, et al. 3-year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. *J Am Coll Cardiol.* 2016;67(22):2565-2574.
34. Conte JV, Hermiller J, Jr., Resar JR, et al. Complications after self-expanding transcatheter or surgical aortic valve replacement. *Semin Thorac Cardiovasc Surg.* 2017;29(3):321-330.
35. Gleason TG, Reardon MJ, Popma JJ, et al. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients. *J Am Coll Cardiol.* 2018;72(22).
36. Food and Drug Administration. Summary Of Safety And Effectiveness Data (SSED): LOTUS Edge TM Valve System. https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180029B.pdf. Accessed March 09, 2021.
37. Arora S, Strassle PD, Ramm CJ, et al. Transcatheter versus surgical aortic valve replacement in patients with lower surgical risk scores: a systematic review and meta-analysis of early outcomes. *Heart Lung Circ.* 2017;26(8):840-845.
38. Arora S, Vaidya SR, Strassle PD, et al. Meta-analysis of transfemoral TAVR versus surgical aortic valve replacement. *Catheter Cardiovasc Interv.* 2017.
39. Garg A, Rao SV, Visveswaran G, et al. Transcatheter aortic valve replacement versus surgical valve replacement in low-intermediate surgical risk patients: a systematic review and metaanalysis. *J Invasive Cardiol.* 2017;29(6):209-216.

40. Singh K, Carson K, Rashid MK, et al. Transcatheter aortic valve implantation in intermediate surgical risk patients with severe aortic stenosis: a systematic review and meta-analysis. *Heart Lung Circ.* 2018;27(2):227-234.
41. Gozdek M, Raffa GM, Suwalski P, et al. Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. *Eur J Cardiothorac Surg.* 2018;53(3):495-504.
42. Khan SU, Lone AN, Saleem MA, et al. Transcatheter vs surgical aortic-valve replacement in low to intermediate- surgical-risk candidates: A meta-analysis and systematic review. *Clin Cardiol.* 2017;40(11):974-981.
43. Tam DY, Vo TX, Wijesundera HC, et al. Transcatheter vs surgical aortic valve replacement for aortic stenosis in low-intermediate risk patients: a meta-analysis. *Can J Cardiol.* 2017;33(9):1171-1179.
44. Witberg G, Lador A, Yahav D, et al. Transcatheter versus surgical aortic valve replacement in patients at low surgical risk: A meta-analysis of randomized trials and propensity score matched observational studies. *Catheter Cardiovasc Interv.* 2018.
45. Ueshima D, Fovino LN, D'Amico G et al. Transcatheter versus surgical aortic valve replacement in low- and intermediate-risk patients: an updated systematic review and meta-analysis. *Cardiovasc Interv Ther.* 2018;34(3).
46. Zhou Y, Wang Y, Wu Y, et al. Transcatheter versus surgical aortic valve replacement in low to intermediate-risk patients: A meta-analysis of randomized and observational studies. *Int J Cardiol.* 2016;228:723-728
47. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *N Engl J Med.* 2016;374(17):1609-1620.
48. Kondur A, Briasoulis A, Palla M, et al. Meta-Analysis of transcatheter aortic valve replacement versus surgical aortic valve replacement in patients with severe aortic valve stenosis. *Am J Cardiol.* 2016;117(2):252- 257.
49. Siemieniuk RA, Agoritsas T, Manja V, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate-risk: systematic review and meta-analysis. *BMJ.* 2016;354:i5130.
50. Sondergaard L, Steinbruchel DA, Ihlemann N, et al. Two-year outcomes in patients with severe aortic valve stenosis randomized to transcatheter versus surgical aortic valve replacement: the all-comers Nordic aortic valve intervention randomized clinical trial. *Circ Cardiovasc Interv.* 2016;9(6).
51. Thyregod HGH, Ihlemann N, Jorgensen TH, et al. Five-year clinical and echocardiographic outcomes from the nordic aortic valve intervention (notion) randomized clinical trial in lower surgical risk patients. *Circ.* 2019.

52. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. *N Engl J Med*. 2017;376(14):1321-1331.
53. National Institute For Health And Care Excellence. Interventional procedure overview of valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (IP 1013/2 [IPG653]). June 2019. <https://www.nice.org.uk/guidance/ipg653/evidence/overview-final-pdf-6834685357>. Accessed March 09, 2021.
54. Phan K, Zhao DF, Wang N, Huo YR, Di Eusanio M, Yan TD. Transcatheter valve-in-valve implantation versus reoperative conventional aortic valve replacement: a systematic review. *J Thorac Dis*. 2016;8(1):E83-93.
55. National Institute For Health And Care Excellence. Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction, Interventional procedures guidance [IPG653]. June 2019. <https://www.nice.org.uk/guidance/ipg653>. Accessed March 08, 2021.
56. Centers for Medicaid and Medicare Services. Decision Memo for Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R). <https://www.cms.gov/medicare-coveredatabase/details/nca-decision-memo.aspx?NCAId=293&bc=ACAAAAAAQAAA&>. Accessed March 08, 2021.
57. Hayes, Inc. Hayes Medical Technology Directory Report. Comparative effectiveness review of transcatheter aortic valve implantation (tavi) and surgical aortic valve replacement (SAVR) for Aortic Stenosis in Lower Risk Patients. Lansdale, PA: Hayes, Inc.; September, 2020.